AGA Clinical Trials

Running trials

• Recruiting

  Comparing the Extent to Which Maridebart Cafraglutide is Made Available in the Body of Participants Living With Overweight or Obesity After Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA)

  NCT07908316· Phase 1· Source

• Recruiting

  Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

  NCT07685808· Phase 2· Source

• Recruiting

  Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

  NCT07575399· Phase 3· Source

• Active, not recruiting

  A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity

  NCT07575932· Phase 2· Source

• Recruiting

  Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

  NCT07271186· Phase 2· Source

• Recruiting

  A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis

  NCT07258849· Phase 1· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Bipolar Disorder (RENEW-Bipolar-1)

  NCT07286175· Phase 2· Source

• Active, not recruiting

  A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults

  NCT06625060· Phase 2· Source

• Recruiting

  Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms

  NCT06559306· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults

  NCT06047444· Phase 3· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults

  NCT06047457· Phase 3· Source

• Recruiting

  A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  NCT05897320· Phase 3· Source

• Recruiting

  A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  NCT05164172· Phase 3· Source

• Recruiting

  A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

  NCT04965675· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Migraine3 recruiting
• Obesity3 recruiting
• Bipolar disorder1 recruiting
• Chronic kidney disease1 recruiting
• Rheumatoid arthritis1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.